home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550091.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
3KB
|
42 lines
Document 0091
DOCN M9550091
TI [New drugs against tuberculosis and nontuberculous mycobacterial
infections: a review]
DT 9505
AU Amitani R; Kuze F; Department of Infection and Inflammation, Kyoto
University,; Japan.
SO Kekkaku. 1994 Nov;69(11):711-7. Unique Identifier : AIDSLINE
MED/95139537
AB The number of cases with tuberculosis is again increasing in many
countries, and recently several nosocomial outbreaks of
multidrug-resistant tuberculosis have occurred in the United States. The
number of patients with disseminated Mycobacterium avium complex (MAC)
infections in AIDS population, and patients with MAC pulmonary disease
unassociated with HIV seem to be also increasing. It takes at least 6 to
9 months for an initial treatment of active tuberculosis due to
drug-sensitive strains with the standard regimen which includes
isoniazid (INH) and rifampicin (RFP). Treatment for the diseases caused
by drug-resistant M. tuberculosis and MAC is much more time-consuming
and more toxic than for the diseases caused by drug-sensitive strains,
and often unsuccessful. For the reasons described above, the
developments of new agents with potent antimycobacterial activities are
highly desired. The new agents should also be useful for treating
patients who have acquired resistance to many of the currently available
drugs. In this review the new antimycobacterial drugs are summarized.
Some of them have already been used clinically, but many are still in
experimental evaluations. 1) Rifamycin derivatives: rifabutin (RBT),
KRM-1648 (KRM), rifapentin (RPT), FCE-22250, FCE-22807, CGP-7040,
SPA-S-565 and other rifamycin derivatives. New rifamycin derivatives
including RBT, KRM have increased in vitro antimycobacterial activities.
RBT and KRM are much more active in vitro and in vivo than RFP against
both M. tuberculosis and MAC. KRM seems to be more potent than RBT
against MAC in experimental studies.(ABSTRACT TRUNCATED AT 250 WORDS)
DE Animal Antitubercular Agents/*THERAPEUTIC USE English Abstract Human
Male Mice Mycobacterium avium-intracellulare Infection/DRUG THERAPY
Mycobacterium Infections, Atypical/*DRUG THERAPY Tuberculosis/*DRUG
THERAPY JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).